Johnson & Johnson (JNJ)
Johnson & Johnson: Don't Bet Against Double Compounding
JNJ bulls often praise its dividends - rightfully. However, the above-average yield and remarkable dividend record understate the attractiveness. Investors should focus on total shareholder returns, which include dividends but also other factors such as EPS growth and buybacks.
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
Eli Lilly's weight loss drugs are pushing the company's market cap toward $1 trillion. Johnson & Johnson is the global leader in drug sales, but its market cap is under $400 billion.
Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $161.43, denoting a +0.79% change from the preceding trading day.
J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition
Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million.
J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy
The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.
J&J Gets FDA Approval of New Chemo-Free Lung Cancer Treatment
Johnson & Johnson (JNJ) on Tuesday announced Food and Drug Administration (FDA) approval of a two-drug, chemotherapy-free treatment plan for certain types of lung cancer, along with an acquisition expanding its offerings to treat heart disease.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Johnson & Johnson Gets FDA Approval for Treatment, Makes Acquisition of Up to $1.7 Billion
The FDA has approved Rybrevant plus Lazcluze in the U.S. for the treatment of patients with non-small cell lung cancer.
J&J to acquire V-Wave for up to $1.7 billion in play for heart failure device
Johnson & Johnson JNJ said Tuesday it has agreed to acquire V-Wave Ltd., a privately held company developing treatments for patients with heart failure, for $600 million upfront and potential extra payments of up to $1.1 billion. V-Wave will become part of Johnson & Johnson Medtech. The deal will help J&J “accelerate its shift into high-growth and high-opportunity markets and will deepen its relationships with structural interventional cardiologists and heart failure specialists,” the company said in a statement. V-Wave's cardiovascular implant technology targets heart failure with reduced ejection fraction, or HFrEF....
J&J to buy medical device maker V-Wave in up to $1.1 bln deal
Johnson & Johnson said on Tuesday it would buy medical device maker V-Wave in a deal potentially worth up to $1.1 billion, marking the latest acquisition to bolster its devices unit.
US FDA approves J&J's combination therapy for type of lung cancer
The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination therapy for patients with a type of non-small cell lung cancer.
Johnson & Johnson wins first FDA approval for chemotherapy-free lung cancer treatment
Johnson & Johnson JNJ, +0.15% said Tuesday the U.S. Food and Drug Administration has approved a combination treatment for a type of lung cancer that's the first chemotherapy-free regimen. The FDA has approved the combination of Rybrevant plus Lazcluze for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, the company said in a statement.
